Alogliptin is a dipeptidyl peptidase-IV inhibitor taken once a day, and was created by Takeda San Diego, Takeda’s wholly-owned subsidiary located in San Diego, California.
Large-scale clinical studies conducted both in Japan and in the world demonstrated that Alogliptin was effective with statistically significant reductions in hemoglobin A1c,- which reflects average blood glucose level over the previous one to two months – and was well-tolerated with no increase in hypoglycemia compared to placebo.
Yasuchika Hasegawa, president of Takeda, said: “Following Alogliptin’s new drug application (NDA) submission in the US in December 2007, we are pleased to accomplish Alogliptin’s new drug application in Japan. We will strive to provide Alogliptin as a new treatment option for type 2 diabetes as early as possible, to patients and healthcare provider in Japan.”